86 related articles for article (PubMed ID: 17392710)
21. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
22. Cancer symposium for the practitioner: introduction to solid tumors.
Adjei AA; Rajkumar SV; Tefferi A
Mayo Clin Proc; 2007 Jan; 82(1):107-9. PubMed ID: 17285792
[No Abstract] [Full Text] [Related]
23. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
[TBL] [Abstract][Full Text] [Related]
24. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
25. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.
Osman N; O'Leary N; Mulcahy E; Barrett N; Wallis F; Hickey K; Gupta R
Ir Med J; 2008 Sep; 101(8):245-7. PubMed ID: 18990955
[TBL] [Abstract][Full Text] [Related]
26. GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
Kolwijck E; Zusterzeel PL; Roelofs HM; Hendriks JC; Peters WH; Massuger LF
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2176-81. PubMed ID: 19661073
[TBL] [Abstract][Full Text] [Related]
27. The paracrine hormone hypothesis of colorectal cancer.
Pitari GM; Li P; Lin JE; Zuzga D; Gibbons AV; Snook AE; Schulz S; Waldman SA
Clin Pharmacol Ther; 2007 Oct; 82(4):441-7. PubMed ID: 17687268
[TBL] [Abstract][Full Text] [Related]
28. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
29. [Contribution of dynamic interpretation of CA 125 measurements to the understanding of an atypical clinical case].
Riedinger JM; Mousseau M; Gauchez AS
Ann Biol Clin (Paris); 2008; 66(3):333-40. PubMed ID: 18558573
[TBL] [Abstract][Full Text] [Related]
30. Tumor cell metabolism: cancer's Achilles' heel.
Kroemer G; Pouyssegur J
Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
[TBL] [Abstract][Full Text] [Related]
31. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
32. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.
Li QX; Yu DH; Liu G; Ke N; McKelvy J; Wong-Staal F
Cell Death Differ; 2008 Aug; 15(8):1197-210. PubMed ID: 18437165
[TBL] [Abstract][Full Text] [Related]
33. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
34. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
36. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
38. An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer.
Ouellet V; Le Page C; Madore J; Guyot MC; Barrès V; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Cancer; 2007 Jul; 110(2):297-308. PubMed ID: 17569106
[TBL] [Abstract][Full Text] [Related]
39. Measuring drug response in sarcoma.
Benjamin R
Clin Adv Hematol Oncol; 2006 Jul; 4(7):513-4. PubMed ID: 17147238
[No Abstract] [Full Text] [Related]
40. [Urinary epithelial cancer].
Muto S; Horie S
Gan To Kagaku Ryoho; 2010 Jan; 37(1):32-4. PubMed ID: 20140992
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
